Product Reports Resources Pricing Login Book a demo
Power Law company profile

MindMed

Biotech & Life Sciences · New York City, United States · Founded 2019 · IPO 2020 Unicorn

A psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness

Valuation
$1.43B
Market cap · Mar/2026
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

19 investors on MindMed's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Kevin O'Leary
Bruce Linton
Series B+ 17 investors entered at this stage
Canaccord Genuity
Special Situations Funds
Woodline Partners
Commodore Capital
Cantor Fitzgerald
Octagon Capital Partners
Leerink Partners
Driehaus Capital Management
Ally Bridge Group
Blake Mycoskie
Bail Capital
Deep Track Capital
Marshall Wace
Janus Henderson Investors
Soleus Capital
Great Point Partners
Cannell Capital

Global footprint

Where MindMed has talent and traffic

Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown
Web traffic by country
16K monthly visits
across markets
🇺🇸 United States56.3%
🇨🇦 Canada14.4%
🇩🇪 Germany11.9%
🇳🇱 Netherlands6.9%
🇮🇳 India5.6%
Top 5 markets shown

Market sentiment

What the market is saying about MindMed

An AI-synthesized read of the highest-engagement posts about MindMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MindMed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles